TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on November 14, 2014, covering events occurring on November 11, 2014. The filing addresses a specific amendment to a compensatory arrangement for the company's Chief Financial Officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance and executive compensation matters and does not contain financial performance data.
Material Changes
The Board of Directors approved an amendment to the Restricted Stock Subscription Agreement of Sean Power, Chief Financial Officer. The amendment modifies the repurchase option lapse schedule by extending the date from November 15, 2014, to March 31, 2015. All other material terms of the original agreement remain unchanged.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is strictly procedural regarding the executive compensation amendment.
Key Facts for Investor Verification
- Sean Power, CFO, received an amendment to his Restricted Stock Subscription Agreement.
- The repurchase option lapse date was extended to March 31, 2015.
- The original agreement was filed as Exhibit 10.33 to the 2011 Form 10-K.
- The amendment was approved by the Board of Directors on November 11, 2014.